Heart Disease News and Research

Latest Heart Disease News and Research

Health Reform Dialogue Coalition releases recommendations for U.S. health care system overhaul

A coalition representing health care firms, patients and medical providers on Friday presented a five-page report to Congress recommending changes to the health care system, CQ HealthBeat reports (Adams, CQ HealthBeat, 3/27).

30 Mar 2009

$78 billion spent for heart disease care in 2006

Opening blocked arteries, trying to keep heart attack victims alive, fixing defective heart valves, and treating other heart ailments cost $78 billion in 2006 - roughly 8 percent of the more than $1 trillion spent on all medical care for the community population, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

30 Mar 2009

Researchers find direct link between oxidative stress and inflammatory signals in the blood

The finding could lead to improved strategies for preventing several diseases by including antioxidants in the diet and for reducing the impact of inflammation in critically ill patients by adding cysteine to intravenous or tube feeding.

30 Mar 2009

Targeted drug therapy prevents exercise-induced arrhythmias

A 12-year-old Dutch boy - bedridden for three years because of an inherited cardiac arrhythmia syndrome - can now join his friends on the soccer field thanks to a discovery made by Vanderbilt University Medical Center researchers.

30 Mar 2009

Corthera's Relaxin in acute heart failure shows promising results

Corthera Inc. has announced that results from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter, randomized, double-blind, placebo-controlled international study, demonstrated promising efficacy and safety for relaxin, the company's investigational drug for treatment of acute heart failure (AHF).

30 Mar 2009

Drug-coated stents lower risk of heart attack and death

Heart disease patients 65 and older who receive stents coated with medicine to prevent blockages are more likely to survive and less likely to suffer a heart attack than people fitted with stents not coated with medication, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the American College of Cardiology's National Cardiovascular Data Registry.

30 Mar 2009

Angiogenesis inhibitor improves glioblastoma survival by reducing edema

The beneficial effects of anti-angiogenesis drugs in the treatment of the deadly brain tumors called glioblastomas appear to result primarily from reduction of edema - the swelling of brain tissue - and not from any direct anti-tumor effect, according to a study from Massachusetts General Hospital (MGH) researchers.

30 Mar 2009

Nile Therapeutics update on phase II CD-NP trial for acute heart failure

Nile Therapeutics, Inc. has announced that, in the course of reviewing the Investigational New Drug (IND) application materials that Nile submitted to the U.S. Food and Drug Administration (FDA) to support the initiation of the Company's Phase IIb clinical trial with CD-NP for the treatment of acute heart failure, the FDA has placed CD-NP on clinical hold.

30 Mar 2009

New Lantheus study finds significant survival benefit for critically ill patients undergoing contrast-enhanced echocardiography

Lantheus Medical Imaging, Inc has announced new data regarding the use of DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension.

29 Mar 2009

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Data from a new study showed that Abbott's TRILIPIX (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium met all of the study's primary endpoints.

29 Mar 2009

Mednet and AT&T to offer wireless heart monitoring

Lifesaving diagnoses and actions, prompted by the anywhere, anytime availability of vital cardiac information, is now more accessible thanks to a wireless heart monitoring solution from Mednet Healthcare Technologies that is powered by AT&T's wireless technologies.

29 Mar 2009

Improved predictive value of biomarkers in HF makes earlier diagnosis and better management possible

With an ever ageing population and more people surviving a heart attack, heart failure is now the world's most prevalent chronic cardiovascular disease.

29 Mar 2009

Improved predictive value of biomarkers in heart failure now makes earlier diagnosis and better management possible

With an ever ageing population and more people surviving a heart attack, heart failure is now the world's most prevalent chronic cardiovascular disease.

29 Mar 2009

Drug-eluting stents found to be safer and superior to bare metal stents

Drug-eluting stents were safe and superior to bare metal stents in preventing death and heart attacks among 262,700 "real-world" patients enrolled in a nationwide registry of cardiovascular disease, according to researchers from Duke University Medical Center.

29 Mar 2009

How fat is stored may explain lower rate of liver disease in African-Americans

Where different ethnic groups store fat in their bodies may account for differences in the likelihood they'll develop insulin resistance and non-alcoholic fatty liver disease, researchers at UT Southwestern Medical Center have found.

29 Mar 2009

ARCA biopharma presents data from phase 3 BEST trial of Gencaro

ARCA biopharma, Inc. has announced that data from the pivotal Phase 3 BEST trial of Gencaro (bucindolol hydrochloride) in patients with advanced chronic heart failure (CHF) was presented at the American College of Cardiology 58 th Annual Scientific Session being held March 29-31, 2009 in Orlando, Florida.

29 Mar 2009

Dapagliflozin trial results indicate improvement in key glycemic measures in treatment-naive type 2 diabetes

Findings published in Diabetes Care from a 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a novel, selective, sodium glucose co-transporter2 (SGLT2) inhibitor, produced clinically meaningful reductions across all key glycemic measures studied [glycosylated hemoglobin level (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG)] in treatment-naive type 2 diabetes patients, compared to placebo.

29 Mar 2009

CRESTOR found to reduced CV risk in patients achieving low LDL-C and hsCRP targets in new Jupiter analysis

Results from a new sub-analysis of the JUPITER study show that patients who attained a dual treatment target of LDL-C <70mg/dL and high-sensitivity C-reactive protein (hsCRP) <2mg/L with CRESTOR (rosuvastatin) 20mg achieved a greater reduction in cardiovascular events compared to placebo than those who did not (65% vs 36%, p=0.033) among men and women with low to normal cholesterol levels and elevated hsCRP.

29 Mar 2009

CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism

A new analysis from the JUPITER study shows that CRESTOR (rosuvastatin) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p=0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP).

29 Mar 2009

A comparative analysis of four beta blocker trials

ARCA biopharma, Inc. has announced that a comparative analysis of primary endpoint data from four beta blocker trials was presented at the American College of Cardiology 58th Annual Scientific Session being held March 29-31, 2009.

29 Mar 2009

Heart Disease News and Research

Latest Heart Disease News and Research

Health Reform Dialogue Coalition releases recommendations for U.S. health care system overhaul

$78 billion spent for heart disease care in 2006

Researchers find direct link between oxidative stress and inflammatory signals in the blood

Targeted drug therapy prevents exercise-induced arrhythmias

Corthera's Relaxin in acute heart failure shows promising results

Drug-coated stents lower risk of heart attack and death

Angiogenesis inhibitor improves glioblastoma survival by reducing edema

Nile Therapeutics update on phase II CD-NP trial for acute heart failure

New Lantheus study finds significant survival benefit for critically ill patients undergoing contrast-enhanced echocardiography

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Mednet and AT&T to offer wireless heart monitoring

Improved predictive value of biomarkers in HF makes earlier diagnosis and better management possible

Improved predictive value of biomarkers in heart failure now makes earlier diagnosis and better management possible

Drug-eluting stents found to be safer and superior to bare metal stents

How fat is stored may explain lower rate of liver disease in African-Americans

ARCA biopharma presents data from phase 3 BEST trial of Gencaro

Dapagliflozin trial results indicate improvement in key glycemic measures in treatment-naive type 2 diabetes

CRESTOR found to reduced CV risk in patients achieving low LDL-C and hsCRP targets in new Jupiter analysis

CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism

A comparative analysis of four beta blocker trials

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Heart Disease News and Research

Latest Heart Disease News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in